Exploring bipolar features in treatment-resistant depression: Insights from the LQD study.

Read full text Summarise with VIRAT
Authors: Devanshi Potdar, Rebecca Strawbridge, Anthony James Cleare, Gianmarco Ingrosso, Rou Qiu
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Treatment-resistant depression (TRD) is typically operationalised as major depressive episodes that have failed to respond to at least two adequate antidepressant trials (Gaynes et al., 2020). It constitutes a clinically severe and heterogeneous form of depressive illness associated with substantial symptom burden and functional impairment. Subthreshold bipolarity has been associated with greater chronicity, poorer response to standard antidepressant strategies (and thus TRD), and higher functional impairment in major depressive disorder. The Lithium versus Quetiapine in Depression (LQD) trial provides an opportunity to study these phenomena in a large, well-characterised TRD sample, as it enrolled adults with persistent depression despite adequate antidepressant trials and followed them over 52 weeks during augmentation with lithium or quetiapine (Cleare et al., 2025). The LQD study excluded people who met criteria for bipolar disorders (BS) but collected measures to characterise bipolar-spectrum features. This study will characterise the prevalence, dimensional structure, and clinical correlates of subthreshold bipolarity in LQD, and will test whether greater bipolar feature burden is associated with higher bipolar symptom severity, poorer wellbeing, and worse 52 week outcomes, irrespective of treatment arm. It then builds on this foundation to ask whether bipolar features matter for treatment choice: specifically, whether baseline bipolarity moderates the relative effectiveness of lithium versus quetiapine and shapes trajectories of bipolar symptoms and clinical response over follow up. Research questions: A: The nature of bipolarity in TRD 1. What proportion of participants show bipolar features? 2. How do bipolar feature measures relate to each other? 3. Are bipolar features associated with other baseline characteristics (those known to be associated with bipolar disorders and wellbeing markers)? B: Change in bipolarity over time 4.To what extent do bipolar symptoms change over 52 weeks? 5.Are baseline bipolar features associated with changes in bipolar symptoms over the 52 weeks? C: Prediction of response 6.Does baseline bipolarity predict clinical response at 52 weeks (alone or in combination with relevant characteristics)? 7.Does baseline bipolarity moderate clinical response to lithium versus quetiapine at 52 weeks? 8.Do changes in bipolar symptoms over time differ by clinical response, between lithium and quetiapine?

Fields of Study & Subjects

Bipolar Disorder and Treatment Treatment of Major Depression Personality Disorders and Psychopathology

Publication details

Publication date
1 January 2026
Language
EN
Document type
Preprint